ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3037% below fair value
$13.24+0.05 (+0.38%)
Close on Nov 12, 2026Market cap $2.97BP/E 17.2Yield –
ADMA Biologics statistics
105 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 6.83
- 2.29
- P/OCF Ratio
- 21.06
- 12.93
Enterprise valuationIndustry
- EV / Sales
- 5.85
- 2.60
- EV / EBIT
- 12.59
- 18.72
- EV / FCF
- 22.85
- 22.07
Share statisticsIndustry
- Shares Change (YoY)
- -4.74%
- 10.9%
- Shares Change (QoQ)
- -1.14%
- 0.51%
- Float
- 217M
- 49M
- Shares Held by Insiders
- 2.98%
- 12.1%
- Shares Held by Institutions
- 91.8%
- 56.4%
Short sellingIndustry
- Short Interest
- 18M
- –
- Short Interest Change
- -7.65%
- -0.76%
- Short % of Float
- 8.30%
- 9.04%
- Short % of Shares Outstanding
- 8.05%
- 6.30%
- Days to Cover
- 7.11
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $20.46
- –
- 52-Week Low
- $7.21
- –
- 20-Day Moving Average
- $11.64
- –
- 50-Day Moving Average
- $10.49
- –
- 200-Day Moving Average
- $10.74
- –
- Average True Range (14)
- $0.64
- –
- Price Change (1 Week)
- 0.23%
- 1.51%
- Price Change (1 Month)
- 28.0%
- -2.35%
- Price Change (3 Months)
- 39.8%
- -21.1%
- Price Change (6 Months)
- 55.8%
- -22.6%
- Price Change (YTD)
- -27.4%
- -22.6%
- Price Change (1 Year)
- -17.4%
- -20.7%
- Price Change (3 Years)
- 254.0%
- -27.4%
- Price Change (5 Years)
- 697.6%
- -77.3%
- Price Change (10 Years)
- 107.5%
- -62.7%
- Average Volume (10 Days)
- 6M
- –
- Average Volume (20 Days)
- 4M
- –
- Average Volume (90 Days)
- 3M
- –
- Relative Volume
- 1.04
- 0.79
- Relative Strength Index (14)
- 68.4
- 44.7
- Volatility (1 Year)
- 59.0%
- 80.4%
- Beta (5 Years)
- 0.64
- 1.07
MarginsIndustry
- Pretax Margin
- 45.2%
- -11.8%
- EBITDA Margin
- 47.9%
- -27.7%
- FCF Margin
- 25.6%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- 41.9%
- -51.2%
- Return on Assets (ROA)
- 28.0%
- -40.6%
- Return on Invested Capital (ROIC)
- 39.4%
- -32.9%
- Return on Capital Employed (ROCE)
- 37.9%
- -38.0%
Financial positionIndustry
- Current Ratio
- 6.04
- 3.30
- Quick Ratio
- 3.08
- 2.42
- Debt / Equity
- 0.45
- 0.49
- Debt / EBITDA
- 0.79
- 3.15
- Debt / FCF
- 1.47
- 4.68
- Net Debt / EBITDA
- 0.29
- 1.97
- Interest Coverage
- 22.80
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 6.26%
- 7.01%
- Net Income Growth (YoY)
- -12.9%
- -14.4%
- EPS Growth (YoY)
- -9.41%
- -11.7%
- FCF Growth (YoY)
- 226.4%
- 7.48%
- Revenue Growth (3Y CAGR)
- 49.0%
- 2.25%
- Revenue Growth (5Y CAGR)
- 64.6%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.80
- 0.40
- Inventory Turnover
- 0.71
- 2.73
- Revenue Per Employee
- $802.40K
- $429.29K
- Profits Per Employee
- $281.94K
- -$683.67K
- Employee Count
- 647
- 75
- WACC
- 7.93%
- 10.1%
Income statement (TTM)Industry
- Pretax Income
- $234.56M
- -$13.23M
Balance sheetIndustry
- Net Cash (Debt)
- -$71.30M
- $17.46M
- Net Cash Per Share
- -$0.32
- $0.72
- Equity (Book Value)
- $438.51M
- $53.27M
- Book Value Per Share
- $1.96
- $1.50
- Tangible Book Value
- $434.40M
- $26.82M
- Working Capital
- $480.59M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$7.89M
- -$944.00K
- FCF Per Share
- $0.59
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- 6.15%
- -20.8%
- FCF Yield
- 4.48%
- -9.58%
- Buyback Yield
- 6.38%
- -0.73%
- Shareholder Yield
- 6.38%
- 0.00%
Taxes and interestIndustry
- Interest Expense
- $10.58M
- $2.93M
- Income Tax
- $52.15M
- $74.00K
- Effective Tax Rate
- 22.2%
- 20.9%
Scores and fair valueIndustry
- Graham Number
- $5.82
- $19.34
- Graham Upside
- -56.0%
- -46.9%
- Altman Z-Score
- 8.58
- 0.30
- Piotroski F-Score
- 5
- 4
- Beneish M-Score
- -0.18
- -2.62
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADMA | S&P 500 | Difference | ADMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +30.1% | -2.7% | +32.8 pts | ||
| 3 months | +35.4% | -1.7% | +37.1 pts | ||
| Year to date | -27.4% | +11.9% | −39.3 pts | ||
| 1 year | -19.6% | +12.0% | −31.5 pts | ||
| 3 years | +251.2% | +78.2% | +173.0 pts | +52.0% | +21.2% |
| 5 years | +697.6% | +73.2% | +624.4 pts | +51.5% | +11.6% |
| 10 years | +107.5% | +309.6% | −202.1 pts | +7.6% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
18M ADMA shares were sold short on Oct 30, 2026, down 7.6% from the previous report, or 8.30% of the shares available to trade. At recent volumes it would take 7.1 days to buy them back. Over the last 20 sessions, 48.6% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 18,035,119 | -7.6% | 2,538,141 | 7.1 |
| Oct 15, 2026 | 19,528,063 | -5.2% | 2,979,743 | 6.5 |
| Sep 30, 2026 | 20,597,867 | -14.9% | 3,633,588 | 5.7 |
| Sep 15, 2026 | 24,206,749 | +1.4% | 2,238,317 | 10.8 |
| Aug 31, 2026 | 23,870,475 | +5.2% | 1,721,995 | 13.9 |
| Aug 14, 2026 | 22,683,647 | +3.5% | 2,843,569 | 8.0 |
| Jul 31, 2026 | 21,918,195 | -8.8% | 2,482,967 | 8.8 |
| Jul 15, 2026 | 24,031,512 | -0.8% | 2,635,962 | 9.1 |
| Jun 30, 2026 | 24,232,698 | +13.9% | 4,167,853 | 5.8 |
| Jun 15, 2026 | 21,280,060 | +7.0% | 3,277,333 | 6.5 |
| May 29, 2026 | 19,897,126 | -0.5% | 3,298,981 | 6.0 |
| May 15, 2026 | 19,994,416 | -3.2% | 8,837,140 | 2.3 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?